Plozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including macrophages and monocytes. Preclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to sites of inflammation. The recruitment of macrophages to the arterial wall is believed to be a critical step in the development of atherosclerosis.

货号（Catalog No.）

CSD00399

通用名INN

Plozalizumab

纯度(Purity)

>95%

浓度( Concentration)

1mg/ml

Formulation

PBS buffer pH7.5

Source

CHO cells

内毒素(Endotoxin level)

Please contact with the lab for this information.

生物活性

产品描述(Description)

Plozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including macrophages and monocytes. Preclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to sites of inflammation. The recruitment of macrophages to the arterial wall is believed to be a critical step in the development of atherosclerosis.

别名(Alternative names)

MLN-1202,anti-CCR2,hu1D9

靶点;物种(Specificity target name;species)

CCR2/CD192[Homo sapiens]

种类(Species)

Humanized

受体鉴定(Receptor identification)

IgG1-kappa

化学信息

CAS

1610761-46-0

存储条件(Storage)

store at -80°C